

IN THE CLAIMS

This listing of the claims replaces all prior versions and listings of claims in the application:

1. (Currently amended) A therapeutic bioconjugate comprising:

(a) a non-proteinaceous hydrophilic polymer; and

(b) one or more peptides selected from the group consisting of SEQ ID NOs 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 68, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, [[124]] 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 200, and 202.

2.-101. (Canceled)

102. (Previously presented) A therapeutic bioconjugate comprising:

(a) a hydrophilic polymer; and

(b) a peptide comprising SEQ ID NO:124.

~~103. (Canceled) The therapeutic bioconjugate of claim 102, wherein the hydrophilic polymer is a polysaccharide.~~

~~104. (Canceled) The therapeutic bioconjugate of claim 103, wherein the polysaccharide is dextran.~~

105. (Previously presented) A therapeutic bioconjugate comprising:

(a) a polysaccharide; and

(b) a peptide comprising SEQ ID NO:124.

106. (New). The therapeutic bioconjugate of claim 105, wherein the polysaccharide is dextran.